Filing Flows › Entrada Therapeutics (TRDA) › Q3 2026
Entrada Therapeutics (TRDA) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Entrada Therapeutics (TRDA) reported revenue of $905K for the third quarter 2026 (Q3 2026), -44% from a year earlier and +0.8% from the quarter before.
Entrada Therapeutics, Q3 2026: revenue $905K (-44% year over year), net loss $39.7M, operating cash flow −$30.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $905K | +0.8% | -44% |
| Operating profit | −$41.7M | — | — |
| Net earnings | −$39.7M | — | — |
| Operating cash flow | −$30.0M | — | — |
What changed
Revenue was $905K in Q3 2026, down 44% year over year and up 1% from the previous quarter.
Operating costs exceeded revenue by $41.7M, an operating margin of -4606.5%. Total costs fell 12% while revenue fell 44%. The quarter ended with a net loss of $39.7M, narrower than the previous quarter's $42.8M loss.
Operating cash flow was −$30.0M. Non-cash charges added back $700K of depreciation and $4.8M of share-based compensation. Working capital and other items added $4.3M. Capital expenditures of $161K exceeded it, leaving free cash flow of −$30.1M.
Questions
What was Entrada Therapeutics' revenue in the third quarter 2026?
Entrada Therapeutics (TRDA) reported revenue of $905K for the third quarter 2026 (Q3 2026), -44% from a year earlier and +0.8% from the quarter before.